Kirsten LundJurgensen - UCB SA Ex Solutions

All Insiders . USA . 
Stock . UCB SA . Stakeholders . Insider . Kirsten LundJurgensen
UCBJF Stock  USD 174.00  0.00  0.00%   

Insider

Kirsten LundJurgensen is Ex Solutions of UCB SA
Age 64
Phone32 2 559 99 99
Webhttps://www.ucb.com

UCB SA Management Efficiency

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.
UCB SA has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Wilson WongSenti Biosciences
N/A
Fanny CavalieFoghorn Therapeutics
46
Lisa MiddlebrookIbio Inc
N/A
Steven BellonFoghorn Therapeutics
59
Ryan MaynardCara Therapeutic
55
Jeffrey EcsedyIkena Oncology
54
John MDVincerx Pharma
N/A
Ming YinBolt Biotherapeutics
N/A
Alfredo CastroIkena Oncology
N/A
Pravin ChaturvediJaguar Animal Health
61
Frdrique MenzaghiCara Therapeutic
58
Deborah KnobelmanSenti Biosciences
50
Carlos CostaFoghorn Therapeutics
51
DVM MSJaguar Animal Health
N/A
Man MBAAdagene
47
Jonathan YinglingArcus Biosciences
55
Jc MDAdagene
59
Dr DScCara Therapeutic
60
Susan KahlertSenti Biosciences
N/A
Jeffrey WelchGeoVax Labs
N/A
Michael MyersQuoin Pharmaceuticals Ltd
62
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. Ucb SA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people. UCB SA [UCBJF] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

Return On Equity0.11
Return On Asset0.0468

UCB SA Leadership Team

Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sandrine CFA, Ex CFO
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
William Silbey, Exec Counsel
Pr LowFriedrich, Chief VP
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
Kirsten LundJurgensen, Ex Solutions
Caroline Vancoillie, Chief Functions
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
JeanChristophe Tellier, Chairman of the Executive Committee, CEO

UCB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.11
Return On Asset0.0468
Profit Margin0.15 %
Operating Margin0.19 %
Current Valuation17.07 B
Shares Outstanding189.96 M
Shares Owned By Insiders38.03 %
Shares Owned By Institutions40.78 %
Price To Earning17.62 X
Price To Book1.52 X

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in UCB Pink Sheet

UCB SA financial ratios help investors to determine whether UCB Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UCB with respect to the benefits of owning UCB SA security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY